Page 40 - GPD-1-2

Gene & Protein in Disease RUNX1 gene in female-related cancers

Figure 7. Formation of cervical cancer by different mutated pathways of RUNX1.
mutation (putative passenger) of 2.3%, have been humanity, technology has been constantly improving and
documented in cervical cancer [136,137] . Several studies changing, and medical discoveries have not lagged behind.
have concluded that micro (mi)RNAs could function Even now, the number of diagnostic facilities, equipped
as a major oncogene or tumor suppressor of various with cutting-edge technology that speeds up the process
cancers by reprogramming NK cell-mediated cytotoxicity and produces precise findings, is growing. Therefore,
to tumor cells by different mechanisms [138,139] . miR-20a identifying mutations in malignancies, particularly those
is a widely known oncomiR that is associated with the linked to RUNX1 disorders, have become much more
development of cervical cancer [140] . In a study, the RUNX1 effective. Every day, there are improvements in therapies,
gene was identified as a direct target of miR-20a, inhibiting and genomic sequences are employed as guidelines for
the killing effect of NK cells to cervical cancer cells by drug development. As a result, RUNX1 mutations are now
negatively regulating RUNX1 gene expression (Figure 7) easy to identify and treat.
[141] . There is emerging evidence showing that RUNX1 gene
is highly expressed in NK T-cells and CD4 T-cells and is Acknowledgment
associated with NK differentiation. Cells participate in the The authors acknowledge the members of the Community
progression of cervical cancer through the modulation of of Biotechnology, Dhaka, Bangladesh, for their support
NK [142] . The treatment for cervical cancer, which includes during the preparation of the manuscript.
surgery, radiation, and chemotherapy, depends on the
stage of cancer, patients’ health issues, and their personal Funding
preferences. Surgeries might include only removing the The authors received no funding from external sources.
carcinoma if the cancer is at the first stage. Immunotherapy
and drug-based treatments are also potential therapies, Conflict of interest
where cell-mediated drugs and various inhibitors against
RUNX1 gene are used to treat cervical cancer [143] . The authors declare that they have no known competing
financial interests or personal relationships that could have
6. Conclusion influenced the work reported in this paper.

Both hematopoietic and non-hematopoietic cancer cells Author contributions
develop and undergo tumorigenesis as a result of RUNX1
mutation or overexpression. However, the role of RUNX1 Conceptualization: Yusha Araf
gene in the activation or inhibition of different tumor cell Supervision: Yusha Araf, Mohammad Jakir Hosen, Chunfu
growth is still unknown, which leaves room for additional Zheng
research. Chromosomal abnormalities result in gene Visualization: MD. Hasanur Rahman, Sagarika Shahriar
mutations, which have a statistically significant association Writing – original draft: Sagarika Shahriar, Zarin Tasnim
with non-hematopoietic cancer in women in particular. Rafa, Maiesha Samiha Mahmood, Deera Mahasin
In addition, the interaction of RUNX1 gene with the Writing - review & editing: Sagarika Shahriar, Zarin
estrogen-ER pathway shows that it has a tight connection Tasnim Rafa, Maiesha Samiha Mahmood, Yusha Araf,
with female reproductive development. Female health Fatama Tous Zohora, Md. Asad Ullah, Md. Akkas Ali,
and reproduction are particularly vulnerable to disorders Mohammad Jakir Hosen
brought on by the RUNX1 gene. Since the dawn of All authors approved the final version of the manuscript.

Volume 1 Issue 2 (2022) 11 https://doi.org/10.36922/gpd.v1i2.147